News
“Effects of MC-1 Alone and in Combination with Lisinopril on Ambulatory BP in Hypertensive Patients with Type 2 Diabetes” presented at the Marine Messe Fukuoka.
WINNIPEG, Manitoba, Oct. 18, 2006--Medicure Inc., a cardiovascular focused biopharmaceutical company, today announced an abstract on the Phase II MATCHED study results with MC-4232 will be presented at the International Society of Hypertension (ISH) conference in Fukuoka, Japan.
Dr. Yves Lacourcière, Director of the Hypertension Research Unit, Centre Hospitalier de l'Université Laval Sainte-Foy, Québec, and the principal investigator for the Phase II MATCHED study will present the abstract during a moderated poster session. The abstract titled “Effects of MC-1 Alone and in Combination with Lisinopril on Ambulatory BP in Hypertensive Patients with Type 2 Diabetes” is scheduled to be presented on Thursday October 19, 2006 at 1:50 PM at the Marine Messe Fukuoka, 7-1 Okihama-machi, Hakata-ku, Fukuoka, Japan.
The Phase II MATCHED study (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) was a randomized, parallel group, cross-over, double-blind, placebo-controlled comparison of 100, 300 or 1000 mg of MC-1 alone and in combination with 20 mg of lisinopril. The study results are based on a population of 120 patients with coexisting type II diabetes and hypertension. The trial was conducted under the guidance and direction of the internationally recognized hypertension specialist, Yves Lacourcière, MD, FRCP, FACP, Director of the Hypertension Research Unit, Centre Hospitalier de l'Université Laval Sainte-Foy, Québec.
About Medicure Inc.
Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:
* Two drugs, MC-1 & MC-4232, in late stage clinical development * Four positive Phase II trials completed with MC-1 * FDA Fast Track designation for MC-1 * U.S. rights to AGGRASTAT® Injection (tirofiban hydrochloride) * Dual action antithrombotic, MC-45308, with positive preclinical results
Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.